IIT Delhi researchers design new strategy for developing drug molecules
Abhiraj P | February 18, 2022 | 07:44 PM IST | 1 min read
IIT Delhi researchers claim that the new drug strategy can also help in treating retroviral infections
A complete guide to IITs: Learn about the admission process, required cutoffs, fees, top branches, campus details, and updated placement statistics—all in one place.
Download NowNEW DELHI: A research team from the Indian Institute of Technology (IIT) Delhi has developed a new drug designing strategy to develop potential drug molecules to treat different diseases.
Must See: IITs Comprehensive Guide
The present strategy of using computer-aided rational drug discovery is time-consuming, claims IIT Delhi. The researchers came up with a different approach where the macromolecular interface are mimicked by small molecules. According to the researchers , the new drug strategy can also help in treating retroviral infections.
Also read | IIT Guwahati, South Dakota Mines collaborate for research on 2D materials, biofilms
According to a statement from IIT Delhi, researchers has made use of organic chemistry and biophysics tools to design molecules that target protein interface. The new method is said to make the drug design approach easier compared to the present methods.
The IIT Delhi researcher team was led by V Haridas, professor at the chemistry department of IIT Delhi. Virologist Guruprasad Medigeshi, who is also a professor at the Translational Health Science and Technology Institute (THSTI), and biochemist Bishwajit Kundu, professor at the Kusuma School of Biological Sciences, IIT Delhi accompanied Haridas in the research.
Also read | IIT Madras research can help detect risk of diabetes, other metabolic diseases early
“We used this strategy to design drug molecules, which could be useful for the treatment of Japanese Encephalitis Virus (JEV), the main cause for viral encephalitis in Southeast Asian countries, and protein aggregation diseases such as Alzheimer’s and other related diseases. We have also patented the JEV inhibitor drug molecule,” said Haridas.
Follow us for the latest education news on colleges and universities, admission, courses, exams, research, education policies, study abroad and more..
To get in touch, write to us at news@careers360.com.
Next Story
]Featured News
]- NCERT to Rashtrapati Bhavan, Doordashan: AICTE’s Anuvadini AI translation tool has grown rapidly
- As ABVP expands footprint in post-TMC West Bengal, SFI, Chhatra Parishad brace for new campus power struggle
- How Samarth portal glitches plague admissions, exams, payments across universities
- IIT Mandi makes attendance must for conference on reincarnation, ‘afterlife communication’
- IIT placements panel discusses ban on sharing of JEE Advanced ranks with recruiters
- CMC Vellore MBBS admissions handpicked doctors who’d serve in India; NEET paper leak renews debate
- IISER Pune plans BS-MS student exchange with other IISERs, more courses for professionals: Director
- West Bengal school teachers deployed for SIR now ordered to join Annapurna Bhandar duties; plan to move court
- IISER Bhopal discontinued BS-MS course over placement issues, offering BTech-MTech degrees: Director
- From next year, CBSE Class 12 answer sheets on Digilocker: Education ministry